Spectrum Pharmaceuticals: Undervalued and (Now) Oversold [View article]
Castle:
Thanks for the comment. I tried to address it and a slew of other things on my mind in the rant above.
Please do NOT mistake my comments as defensive or specifically aimed at you. That was NOT at all my intention. You will find that I addressed your concern and agreed with your sentiment - where I indicated that traders should naturally wait for confirmation.
I think where I might disagree with you is the 50/50 comment you made. From my view, that does not seem very accurate or fair based on the facts. With that said, I am not sure where you came up with that risk/reward ratio. Before responding, I would like to offer you a chance to elaborate.
Spectrum Pharma: Post-Zevalin Approval Sales Should Ramp Up [View article]
User No. 476774:
Did you read the article featured above or just rush to post your brilliant comment?
I addressed the downgrade.
I think shares remain undervalued at the current price and believe that a more appropriate market cap for this company is $500 M based on the Zevalin approval alone. At that value, shares would trade around $11.90. I believe shares will likely reach and exceed $11.90 within the next 90 days or less.
Obviously, price targets are adjusted when the company sells its stock. The projected market value of the company, which I have conservatively estimated at $1.12 billion within 12-18 months (or less), has not changed. My sentiment about SPPI remains the same.
A retest of the 50 MA hardly creates a cause for concern. Nice try. Investors here are smarter than you apparently believe - as you try to play the "gotcha" game with me. The problem for you is that you haven't got anything to get me with. Your methodology is not at all persuasive. Sadly, you've had it rough throughout your entire life.
As far as Fusilev, I am sticking with my call. I think the odds favor an approval and by 85% or greater. At what specific price will shares trade if the company successfully obtains approval for Fusilev on 10/8/09? I have not a clue.
What I can tell you is that I believe SPPI is way undervalued at the current price. I am confident that shares will move higher from here. Following the Zevalin approval, I believe a more appropriate value for SPPI is at or above $500 million or a share price of $11.90. As I said above, I remain confident it will get there before year-end.
When shares do begin to advance, you will magically disappear until the next pullback. It is funny how that works.
I'm not hiding on this end.
Justin
PS. Please try to improve your grammar and spelling.
Spectrum Pharma: Post-Zevalin Approval Sales Should Ramp Up [View article]
New id - how many does this make? Bertrt, SPPI-analyst, and now your prison number. Nice work.
Regarding the alleged data that you want me to look up, it is not readily available.
Next time, I will itemize and date everything for you. Kidding, I won't. I thought I was the slow one here, but you really take the cake. Obviously, the other 66K followed - hence the use of periods. The point was made, and yet again you cannot refute it - other than to play some silly game by quickly summing up that I disproved my own point.
Nothing I have said aims to prove anything. I build my case and you have consistently been way off - not even close to the ballpark.
Why waste your time and all of your negative energy? You continue to lose. Honestly, you really do not have a clue about what the heck you're talking about.
If there is data, present it. Make your case. Rather than play games with me - "disprove" me.
Spectrum Pharma: Post-Zevalin Approval Sales Should Ramp Up [View article]
Is it really that simple?
Why did sales suddenly - out of nowhere - increase 25% Q over Q for the first time in 3 years. I suppose you will shrug that off too. Shrug off the expansion to include all 66K NHL patients from 28K.
You have clearly demonstrated that you have absolutely no idea why the drug was not used or why it will be used in the future. Off-label arguments are totally ignorant and irrelevant here.
As for the pullback, who cares? The pattern is established. See the chart above. When you take shares down and break the underlying trend, I will concede. Otherwise, a smack talker with no identity is just another coward.
Take a hike.
Since you'll continue to come back - obsessive nut - I would appreciate it if you would try to write in complete thoughts. Please use the new spell check feature! Thanks!
On Sep 11 03:51 PM User 482586 wrote: And I'll keep laughing as this keeps falling.
Constructive point, which longs won't like because it will cost them $, is that lable expansions in chemo don't lead to increased revenue due to off lable use already. check sales of other oncol drugs post sNDA approval. Simple......
Spectrum Pharmaceuticals: Rumors of Buyout Talks Persist [View article]
Makk:
I respectfully disagree. A credible source was cited via FlyontheWall.
As you know, no intelligent investor will run out and buy SPPI based on this information alone. With that said, the rumor is a new and I believe an important development - one I had absolutely nothing to do with.
In the past, I have found the FlyontheWall to be accurate more times than not. For this reason, I believe the rumor is worth noting.
I know you from past discussions and certainly respect your opinion. On this occassion, however, we just see things differently. Nevertheless, I do hope you will continue to post comments in the future.
More on Citigroup (C): In addition to Pandit's departure, COO John Havens is also stepping down. The board selects Michael Corbat - who previously served as the bank's CEO of Europe, Middle East and Africa - as new Citigroup CEO. Havens had been planning to retire at year's end, but given Pandit's move, decided now was the time. (PR) [View news story]
Hard to say. But I agree Galt, it's odd. Citi's stock will take a hit.
Bank Of America: Breakout Or Breakdown? [View article]
RS, you are dead on here. Profit taking or not, everyone should stay the course with BAC.
While I am certainly no Obama supporter, yesterday's jobs' numbers were very positive. This development was a game changer and should not be overlooked by investors.
With a positive Q1 2012 report, BAC could potentially trade at $12 by May 2012. So, you're target, $15-$16 area, is very reasonable for your time frame of 12-18 months. I project BAC will trade between $15 and $20 by the January 2013 expiration date.
I am confident that you and I as well as our other friends, holding equity in BAC, will enjoy a very profitable 2012. Great job again RS!
Spectrum Pharmaceuticals: Undervalued and (Now) Oversold [View article]
Thanks for the comment. I tried to address it and a slew of other things on my mind in the rant above.
Please do NOT mistake my comments as defensive or specifically aimed at you. That was NOT at all my intention. You will find that I addressed your concern and agreed with your sentiment - where I indicated that traders should naturally wait for confirmation.
I think where I might disagree with you is the 50/50 comment you made. From my view, that does not seem very accurate or fair based on the facts. With that said, I am not sure where you came up with that risk/reward ratio. Before responding, I would like to offer you a chance to elaborate.
Thanks in advance!
Justin
Spectrum Pharma: Post-Zevalin Approval Sales Should Ramp Up [View article]
User No. 476774:
Did you read the article featured above or just rush to post your brilliant comment?
I addressed the downgrade.
I think shares remain undervalued at the current price and believe that a more appropriate market cap for this company is $500 M based on the Zevalin approval alone. At that value, shares would trade around $11.90. I believe shares will likely reach and exceed $11.90 within the next 90 days or less.
Obviously, price targets are adjusted when the company sells its stock. The projected market value of the company, which I have conservatively estimated at $1.12 billion within 12-18 months (or less), has not changed. My sentiment about SPPI remains the same.
A retest of the 50 MA hardly creates a cause for concern. Nice try. Investors here are smarter than you apparently believe - as you try to play the "gotcha" game with me. The problem for you is that you haven't got anything to get me with. Your methodology is not at all persuasive. Sadly, you've had it rough throughout your entire life.
As far as Fusilev, I am sticking with my call. I think the odds favor an approval and by 85% or greater. At what specific price will shares trade if the company successfully obtains approval for Fusilev on 10/8/09? I have not a clue.
What I can tell you is that I believe SPPI is way undervalued at the current price. I am confident that shares will move higher from here. Following the Zevalin approval, I believe a more appropriate value for SPPI is at or above $500 million or a share price of $11.90. As I said above, I remain confident it will get there before year-end.
When shares do begin to advance, you will magically disappear until the next pullback. It is funny how that works.
I'm not hiding on this end.
Justin
PS. Please try to improve your grammar and spelling.
Spectrum Pharma: Post-Zevalin Approval Sales Should Ramp Up [View article]
Regarding the alleged data that you want me to look up, it is not readily available.
Next time, I will itemize and date everything for you. Kidding, I won't. I thought I was the slow one here, but you really take the cake. Obviously, the other 66K followed - hence the use of periods. The point was made, and yet again you cannot refute it - other than to play some silly game by quickly summing up that I disproved my own point.
Nothing I have said aims to prove anything. I build my case and you have consistently been way off - not even close to the ballpark.
Why waste your time and all of your negative energy? You continue to lose. Honestly, you really do not have a clue about what the heck you're talking about.
If there is data, present it. Make your case. Rather than play games with me - "disprove" me.
I do not believe you can.
Spectrum Pharma: Post-Zevalin Approval Sales Should Ramp Up [View article]
Why did sales suddenly - out of nowhere - increase 25% Q over Q for the first time in 3 years. I suppose you will shrug that off too. Shrug off the expansion to include all 66K NHL patients from 28K.
You have clearly demonstrated that you have absolutely no idea why the drug was not used or why it will be used in the future. Off-label arguments are totally ignorant and irrelevant here.
As for the pullback, who cares? The pattern is established. See the chart above. When you take shares down and break the underlying trend, I will concede. Otherwise, a smack talker with no identity is just another coward.
Take a hike.
Since you'll continue to come back - obsessive nut - I would appreciate it if you would try to write in complete thoughts. Please use the new spell check feature! Thanks!
On Sep 11 03:51 PM User 482586 wrote:
And I'll keep laughing as this keeps falling.
Constructive point, which longs won't like because it will cost them
$, is that lable expansions in chemo don't lead to increased revenue due to off lable use already. check sales of other oncol drugs post sNDA approval. Simple......
Ariad Pharmaceuticals: Significant Catalysts Approaching [View article]
You should familiarize yourself with our Constitution.
I owe you nothing more than an honest opinion, which I provided. I disclosed my position. What more do you want?
I strongly encourage you to check my track record. Try reading my other articles.
Justin
Spectrum Pharmaceuticals: Rumors of Buyout Talks Persist [View article]
I respectfully disagree. A credible source was cited via FlyontheWall.
As you know, no intelligent investor will run out and buy SPPI based on this information alone. With that said, the rumor is a new and I believe an important development - one I had absolutely nothing to do with.
In the past, I have found the FlyontheWall to be accurate more times than not. For this reason, I believe the rumor is worth noting.
I know you from past discussions and certainly respect your opinion. On this occassion, however, we just see things differently. Nevertheless, I do hope you will continue to post comments in the future.
Thank you for your feedback.
Justin
More on Citigroup (C): In addition to Pandit's departure, COO John Havens is also stepping down. The board selects Michael Corbat - who previously served as the bank's CEO of Europe, Middle East and Africa - as new Citigroup CEO. Havens had been planning to retire at year's end, but given Pandit's move, decided now was the time. (PR) [View news story]
Why We Can't Simplify Bank Regulation [View article]
Please cut the communist "nationalize the banks" crap and use your noodle to think.
Good grief.
ECRI Reaffirms Recession Call [View article]
So, I share and agree with your sentiment here.
Justin
Bank Of America Potentially Setting Up For Big Move [View article]
Bank Of America: Breakout Or Breakdown? [View article]
While I am certainly no Obama supporter, yesterday's jobs' numbers were very positive. This development was a game changer and should not be overlooked by investors.
With a positive Q1 2012 report, BAC could potentially trade at $12 by May 2012. So, you're target, $15-$16 area, is very reasonable for your time frame of 12-18 months. I project BAC will trade between $15 and $20 by the January 2013 expiration date.
I am confident that you and I as well as our other friends, holding equity in BAC, will enjoy a very profitable 2012. Great job again RS!
Justin
Bank Of America Well Positioned For A Big Move (Follow-Up) [View article]
I'm with you sir. Hence the $15 - $20 target range by 1/18/13. :-)
I think many here will be surprised, presuming they hang on and don't get distracted.
As for me, I'm focused my friend. :-)
Good luck with your position via BAC warrants.
Justin
Bank Of America Well Positioned For A Big Move (Follow-Up) [View article]
Bank Of America Well Positioned For A Big Move (Follow-Up) [View article]
Thank you for taking the time to review my article. I genuinely appreciate it.
Justin M. Hall
Is Patriot Coal Headed For Bankruptcy? [View article]